Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Beta-thalassemia is one of the most frequently inherited disorders caused by mutations in the beta globin gene or its promoter, leading to reduced or absent beta globin synthesis. Ineffective erythropoiesis (IE) and consequent extramedullary hematopoiesis, splenomegaly and systemic iron overload are major features of this disease. The disease course can be associated with severe anemia and need for lifelong transfusion therapy (thalassemia major, TM) or relatively less severe anemia (non-transfusion-dependent thalassemia, NTDT, or thalassemia inter-media, TI). Patients affected by beta-thalassemia intermedia do not require chronic blood transfusions for survival. However, transfusion-independence is still associated with a variety of serious clinical morbidities.1–3 In NTDT the master regulator of iron homeostasis, hepcidin (Hamp), is chronically repressed.4–7 Therefore, patients absorb abnormally high levels of iron, requiring iron chelation to prevent the clinical sequelae associated with iron overload. Iron homeostasis needs to be carefully regulated in order to avoid toxicity due to its excess. If untreated, iron overload leads to organ failure and death. For this reason, in beta-thalassemia and other iron-related disorders, the management of iron overload has become the main focus. Chelation therapy, however, does not target the mechanism responsible for abnormal iron absorption, which is low levels of Hamp expression and synthesis. It has been shown that in mice affected by NTDT (Hbbth3/+ or th3/+), second generation antisense oligonucleotides (Tmprss6-ASO) or lipid nanoparticle (LNP)-formulated siRNAs can reduce the expression of transmembrane serine protease Tmprss6, one of the major suppressors of hepcidin expression.8,9 Suppression of Tmprss6 led to an increase in hepcidin synthesis and hemoglobin levels. These observations were also associated with a net reduction in splenomegaly, iron overload, transferrin saturation (TfSat), formation of insoluble membrane-bound globins (hemichromes) and reactive oxygen species (ROS).9 Thus, we hypothesized that the simultaneous use of the iron chelator deferiprone (DFP) with Tmprss6-ASO (Tmprss6-ASO+DFP) could combine the positive effects of Tmprss6-ASO on erythropoiesis and iron absorption with the chelation benefit on organ iron content. In this study, 3- to 4-month-old Hbbth3/+ females were treated with 50 mg/kg of Tmprss6 antisense oligonucleotide (Tmprss6-ASO, twice a week for 6 weeks) or Tmprss6-ASO in combination with the oral iron chelator DFP dissolved in the drinking water at 1.25 mg/ml, using either a commercial diet (normally used in the facility where animals were housed) containing 200 ppm of iron, or a physiological diet containing 35 ppm of iron. The majority of the animals available were treated using the commercial diet and just a few animals per group received the physiological one. With both diets we obtained the same trend in behavior, but considering that the numbers were not comparable, we decided to show only the data obtained from the 200 ppm diet. As expected, Tmprss6-ASO treatment, alone or in combination with DFP, suppressed Tmprss6 expression in the liver reaching an 82% decrease (P<1.8E-08) (Figure 1A). This was associated with a significant increase in Hamp expression (Figure 1B). DFP alone did not induce any changes in Tmprss6 or Hamp levels (Figure 1A,B). However, as expected, DFP was efficient in reducing liver iron content both in wild-type (WT) and Hbbth3/+ animals (Figure 1C). Tmprss6-ASO alone showed a trend towards reducing liver iron concentration when compared with scrambled-ASO treated animals (Figure 1C). The level of reduction achieved by Tmprss6-ASO alone is lower than that which we previously published. This could be due to a number of reasons. Animals used in this study were younger and showed a lower level of iron accumulation to start with. In addition, we observed a bigger variability in the results, mostly in scrambled-ASO treated animals, which apparently reduces the effect of the Tmprss6-ASO. Regardless, in combination with DFP the antisense oligonucleotide achieved a significantly greater reduction in iron content when compared with each agent separately or with scrambled-ASO controls. Of note, similar results were also observed by Schmidt PJ, et al. in their recent publication using siRNAs against Tmprss6 in combination with DFP in the same mouse model of thalassemia intermedia.10 The ratio between Hamp expression and liver iron concentration (LIC) (Table 1), highlights the concept that to achieve iron restriction in this mouse model of beta-thalassemia increased Hamp expression is necessary. Even though administration of DFP alone was successful in decreasing liver iron content, with a reduction of 38% (Figure 1C), it failed to improve parameters of erythropoiesis such as hemoglobin (Hgb) levels (Figure 2A), red blood cell (RBC) production (Figure 2B) spleen weight (Figure 2C) and RBC morphology (Figur
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., Hettinger, J., Bumcrot, D., & Fleming, M. D. (2013) · Blood · doi:10.1182/blood-2012-09-453977 · Cited by 204
Ginzburg, Y., & Rivella, S. (2011) · Blood · doi:10.1182/blood-2011-03-283614 · Cited by 201
Self-citationRedistribution of accumulated cell iron: a modality of chelation with therapeutic implications
Sohn, Y.-S., Breuer, W., Munnich, A., & Cabantchik, Z. I. (2008) · Blood · doi:10.1182/blood-2007-07-102335 · Cited by 167 · cited 1×
“This holotransferrin-bound iron can be transferred and become available for hemoglobin synthesis.(11) Amelioration of erythropoiesis in this model of NTDT requires decreased erythroid iron intake and hemichrome formation.”
BackgroundWeizer‐Stern, O., Adamsky, K., Amariglio, N., Levin, C., Koren, A., Breuer, W., Rachmilewitz, E., Breda, L., Rivella, S., Ioav Cabantchik, Z., et al. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06258.x · Cited by 80
Self-citationSchmidt, P. J., Racie, T., Westerman, M., Fitzgerald, K., Butler, J. S., & Fleming, M. D. (2015) · American Journal of Hematology · doi:10.1002/ajh.23934 · Cited by 77
Weizer-Stern, O., Adamsky, K., Amariglio, N., Rachmilewitz, E., Breda, L., Rivella, S., & Rechavi, G. (2006) · American Journal of Hematology · doi:10.1002/ajh.20549 · Cited by 71
Self-citation
Cited by
A Red carpet for iron metabolism
Muckenthaler, M. U., Rivella, S., Hentze, M. W., & Galy, B. (2017) · Cell · doi:10.1016/j.cell.2016.12.034 · Cited by 1,319
Self-citationTargeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Self-citationKattamis, A., Kwiatkowski, J. L., & Aydinok, Y. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00536-0 · Cited by 313
Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera
Casu, C., Oikonomidou, P. R., Chen, H., Nandi, V., Ginzburg, Y., Prasad, P., Fleming, R. E., Shah, Y. M., Valore, E. V., Nemeth, E., et al. (2016) · Blood · doi:10.1182/blood-2015-10-676742 · Cited by 148
“This indicates that treatment with the iron chelator alone was not sufficient to improve erythropoiesis, despite reduced organ iron content.(23) Reticulocyte count and spleen size were both reduced with M009 and M009 1 DFP treatment, reflecting improved erythropoietic efficiency (Figure 4D-E).”
Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia
Rivella, S. (2019) · Blood · doi:10.1182/blood-2018-07-815928 · Cited by 120
Self-citation
Metadata
- Authors
- Casu, C., Aghajan, M., Oikonomidou, P. R., Guo, S., Monia, B. P., & Rivella, S.
- Venue
- Haematologica
- Published
- 2015-09-24
- Volume
- 101
- Issue
- 1
- Pages
- e8-e11
- ISSN
- 0390-6078 (ISSN-L)
- 1592-8721
- OpenAlex
- W2239159058
- Cited by
- 79
- References
- 6
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. https://app.cochat.ai/papers/10.3324/haematol.2015.133348
- The paper
- Casu, C., Aghajan, M., Oikonomidou, P. R., Guo, S., Monia, B. P., & Rivella, S. (2016). Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia. Haematologica. https://doi.org/10.3324/haematol.2015.133348
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.